1stOncology™: Cancer Intelligence Service – Page 6050 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

On March 14, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, reported that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference (Press release, Aldeyra Therapeutics, MAR 14, 2022, View Source [SID1234610055]). The conference is being conducted in a virtual format March 15-17, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Dr. Brady’s conversation with Justin Kim, Senior Analyst, Biotech Equity Research at Oppenheimer, is scheduled to begin at 11:20 a.m. ET Wednesday, March 16, 2022. A webcast of the presentation can be accessed on the Investors & Media section of the Aldeyra website at View Source Following the presentation, the webcast will be archived for 90 days.

KIYATEC to Present New Clinical Correlation Data at American Association for Cancer Research

On March 14, 2022 KIYATEC, the leader in clinically correlated, published functional precision oncology technology reported that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, KIYATEC, MAR 14, 2022, View Source [SID1234610054]). The meeting will be held in New Orleans from April 8 – 13, 2022 .

KIYATEC’s clinical and pre-clinical technology platforms, 3D PredictTM and KIYA-PREDICTTM, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. The six abstracts accepted for presentation at the conference include applications in multiple tumor types, immunotherapy drug response, and ex vivo application of PDX for pre-clinical drug development. These works feature collaborations with investigators from XenoSTART and the Adenoid Cystic Carcinoma Research Foundation.

"We are proud to showcase our research at the upcoming AACR (Free AACR Whitepaper) conference," said Tessa DesRochers, Ph.D., Chief Scientific Officer at KIYATEC. "The collection of abstracts demonstrates our dedication to leading with evidence. Our strong data demonstrates that our approach works."

Session titles and information for the abstracts are listed below and are also available on the AACR (Free AACR Whitepaper) online itinerary planner. KIYATEC will exhibit at AACR (Free AACR Whitepaper) at Booth #1449.

KIYATEC presentation schedule:

Ex vivo 3D drug response profiling of XPDX-derived tumor cells for acceleration of preclinical drug development
3D models and Microfluidics, Section 9
April 10th 1:30 – 5 PM

Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response
3D models and Microfluidics, Section 9
April 10th 1:30 – 5 PM

Engineered 3D tissues facilitate preclinical immunotherapy studies in fully human platforms
Tissue Recombinant, Organ slide, and Decellularized Models, Section 14
April 10th 1:30 – 5 PM

3D PredictTM, an analytically and clinically validated platform for evidence-based functional precision medicine
Biomarkers Predictive of Therapeutic Benefit, Section 31
April 12th 9 AM – 12:30 PM

Organoids standardized to a clinically validated drugs response assay for truly predictive in vitro drug response profiling
Organoid-based models, Section 9
April 12th 1:30 – 5 PM

Dissecting personalized PD-1 inhibitor efficacy using patient-derived 3D spheroids
Vaccines/Immunomodulatory Agents and Interventions, Section 34
April 13th 9 AM – 12:30 PM

AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022

On March 14, 2022 AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, reported that it will report financial results for the third quarter of fiscal year 2022 before the market open on Thursday, April 7, 2022 (Press release, AngioDynamics, MAR 14, 2022, View Source [SID1234610053]). The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13727875.

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Thursday, April 7, 2022, until 11:59 p.m. ET on Thursday, April 14, 2022. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13727875.

Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan

On March 14, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumors (Press release, Guardant Health, MAR 14, 2022, View Source [SID1234610052]).

MHLW also approved Guardant360 CDx as a companion diagnostic to identify patients with microsatellite instability-high (MSI-High) solid tumors who may benefit from Keytruda (pembrolizumab) and patients with MSI-High advanced colorectal cancer (CRC) who may benefit from Opdivo (nivolumab). In December 2021, MHLW granted regulatory approval of Guardant360 CDx as a companion diagnostic for identifying patients with metastatic non-small cell lung cancer (NSCLC) who may benefit from treatment with LUMAKRAS (sotorasib).

"The MHLW approval of Guardant360 CDx marks a significant milestone for Guardant Health and further reinforces the value blood-based testing brings to physicians and patients with advanced cancer. With a simple blood draw, a physician can conduct comprehensive genomic profiling of a patient’s tumor, then match that patient with the best available treatment option without the complications and delays of a tissue biopsy," said Helmy Eltoukhy, Guardant Health co-CEO. "Today’s approval further strengthens Guardant Health’s global commitment to transform cancer care by bringing innovative blood-based tests like Guardant360 CDx to physicians and advanced cancer patients in Japan."

About Guardant360 CDx

Guardant360 CDx is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from the blood samples of patients with advanced solid tumors and identifies genetic alterations that may inform treatment decisions. On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360 CDx for comprehensive genomic profiling across all solid cancers and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso (osimertinib). This approval represented the first FDA-approved liquid biopsy test for comprehensive tumor mutation profiling across all solid cancers.

Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

On March 14, 2022 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, reported it has received a Notice of Allowance from the U.S. Patent and Trademark Office (PTO) for its invention titled "Method for Treating Fibrotic Liver Tissue Using CL-IB MECA" (Press release, Can-Fite BioPharma, MAR 14, 2022, View Source [SID1234610051]).

Currently, Namodenoson (CL-IB-MECA) is being developed for two liver indications, liver cancer and NASH. The allowance granted by the US PTO opens the door for much broader market needs which entail all clinical conditions with advanced liver fibrosis including autoimmune hepatitis, primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD) among others. The global liver disease treatment market was valued at approximately $20 billion in 2020 by Allied Market Research.

Can-Fite is currently enrolling patients in a Phase IIb trial of Namodenoson for the treatment of NASH, an advanced non-alcoholic fatty liver disease, for which there is no U.S. FDA approved treatment. Additionally, the Company expects to commence enrollment in a pivotal Phase III study of Namodenoson in the treatment of advanced liver cancer (hepatocellular carcinoma CPB7).

Can-Fite’s robust IP portfolio includes patents that address NASH and liver cancer, issued in approximately 40 countries. Namodenoson has been out-licensed in select countries for the treatment of NASH and liver cancer with agreements that include upfront and milestone payments.

"This U.S. patent is a very important addition to our growing IP portfolio in liver diseases. It is very well timed with our Phase IIb NASH study and Phase III liver cancer trial. Both are high value indications in which our robust patent portfolio and Namodenoson’s safety and efficacy profile position Can-Fite for potential additional strategic distribution deals worldwide," stated Can-Fite CEO Dr. Pnina Fishman.

About NASH

There is currently no U.S. FDA approved treatment for NASH, an addressable pharmaceutical market estimated to reach $35-$40 billion by 2025 driven by increasing incidence. The U.S. National Institutes of Health estimate the prevalence of NASH in the U.S. at 2-5% of the population. NASH is the leading cause for liver transplants among women and second leading cause overall in the U.S. Given the rate of increase, it is expected to become the leading indication for liver transplants in males as well.

About HCC

Hepatocellular carcinoma (HCC) is the most common form of liver cancer. HCC with underlying Child Pugh B7 (CPB7) is one of the most advanced forms of liver cancer. More than 800,000 people are diagnosed with liver cancer annually and approximately 700,000 die of the disease each year, according to the American Cancer Society. The HCC drug market is projected to reach $3.8 billion by 2027.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.